|
Post by kc on Sept 25, 2018 14:38:24 GMT -5
Mike starts at the 1:48 mark. Good presentation.
|
|
|
Post by kc on Sept 4, 2018 14:19:23 GMT -5
Broke $2 per share. Β Day is getter more fun. CC I have to agree with you. The last four or five months I have been laying low because itβs upsetting to see the share price. Perhaps we will gain some momentum. This is a good deal for United therapeutics as their current device is so big and bulky that using a Technosphere type device opens a new market for them at a reduced cost of producing drug. Wider access to people who need this type of medication will be big for both companies. There are a lot of people with untreated COPD.
|
|
|
Post by kc on Sept 4, 2018 5:58:25 GMT -5
Validation of Technosphere.
|
|
|
Post by kc on Sept 4, 2018 5:39:11 GMT -5
Great to see that we are going to partner with United therapeutics as this is a great step forward for MannKind. He is great validation to the Technosphere do you vice delivery system. Congratulations to Mike and the MannKind team.
|
|
|
Post by kc on Aug 20, 2018 17:03:05 GMT -5
Mike should create the Paradigm shift in how Insulin is marketed with a EXTREME PARADIGM SHIFT IN PRICING.
|
|
|
Post by kc on Jun 26, 2018 20:14:00 GMT -5
You guys can spin it all you want but reducing time spent in hypoglycemia (i.e., <70 mg/dl) by 41% and increasing time-in-range by an average 12% per day is a big deal over years of a diabetics life. More inportantly is the cost of an emergency room visit caused by a hypoglycemic incident. That is the true cost of not using Afrezza.
|
|
|
Post by kc on Jun 22, 2018 11:25:12 GMT -5
The Kendall effect, notice how they are emphasizing the delivery via lungs now and the benefits as opposed to the FUD that has been used, he is taking the correct perspective via the physiological aspects and technology of Afrezza and TI. Talking directly to the Doctor's..... nice web site change
When your patients are not at glycemic target, choose Afrezza, the only available inhaled option that delivers a rapid insulin response
|
|
|
Post by kc on Jun 20, 2018 21:24:57 GMT -5
You would think that every Physician that has had anything to do with Diabetes would be wanting to learn more about Afrezza !! 5.fricken7 A1c !! Thatβs incredible, very happy for you. ππ»ππ»ππ»ππ»ππ»ππ» Actually, this was an update. A1C now 5.6 π Congratulations. 5.6 great achievement. Iβm not diabetic but had my physical yesterday. I will see what mine is in a couple of days. I assume they tested it. Last time my Glucose Serum was high.
|
|
|
Post by kc on Jun 20, 2018 21:02:00 GMT -5
With script sales approaching 800,000 per week the market can see the upward momentum. Management might also be seeing the signs of it breaking $1,000,000 in the next couple of weeks. They know they can show the future if week over week sales continue upwards.
|
|
|
Post by kc on Jun 20, 2018 18:12:51 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? Interestingly, the Lotte New York Palace Hotel was formerly known as The Helmsley Palace Hotel. That name Helmsley keeps popping up today, in connection with Mannkind.Yes good point on Helmsley.....The Helmsley Charitable Foundation is a big supporter of Diabetes research. helmsleytrust.org/programs/health-type-1-diabetes
In the case of holding it at the Lotte Hotel that is probably just a coincidence.
I do believe at sometime in the past that I heard of a connection to Helmsley foundation and MannKind.
|
|
|
Post by kc on Jun 20, 2018 17:58:26 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? Don't forget Aegis investments ......I am issuing you a YELLOW CARD.......
|
|
|
Post by kc on Jun 20, 2018 15:22:57 GMT -5
Nice that they engaged Dr. Edelman very credible user. An expert in diabetes.
Kaboom!
|
|
|
Post by kc on Jun 19, 2018 21:48:15 GMT -5
Insulin degludec is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.
Afrezza and Tresiba.
|
|
|
Post by kc on Jun 19, 2018 21:08:53 GMT -5
Does anybody know what this Abstract says about Afrezza? www.ncbi.nlm.nih.gov/pubmed/29718785/Postgrad Med. 2018 May;130(4):409-410. doi: 10.1080/00325481.2018.1472509. Epub 2018 May 14.Finally, after 56 years of type 1 diabetes: a regimen that works. Bell DSH1. Author information Abstract Prior to the availability of degludec and regular human insulin inhalation powder in the type 1 diabetic patient glycemic control with subcutaneous insulin injections was difficult to obtain due to nocturnal, pre-prandial and often severe hypoglycemia as well as post-prandial hyperglycemia and hypoglycemia due to 'stacking' of insulin. A 62-year-old female with type 1 diabetes for 56 years who could not be controlled with continuous subcutaneous insulin aspart infusion obtained glycemic control without significant hypoglycemia or increased post-prandial glycemic excursions utilizing degludec insulin for basal needs and technosphere before meals and between meals if needed. The availability of degludec and technosphere insulin improved the management of brittle type 1 diabetes.KEYWORDS: Diabetes mellitus type 1; degludec insulin; hypoglycemia; post-prandial hyperglycemia; regular human insulin inhalation powder
|
|
|
Post by kc on Jun 19, 2018 21:00:04 GMT -5
I have said 100 times over 4 years β- Doctors are very slow to change what they think is working as they are just old school steady Eddieβs. They have been wined and dined by the big 3 for too many years and enjoy the perks.
If we stay financially viable we will make it and be a blockbuster game changing product for diabetics.
|
|